Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$74.18−3.48 (-4.48%)
Close on Nov 17, 2026Market cap $1.09BP/E –Yield –
Inhibrx Biosciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Inhibrx Biosciences's total debt was $276.70M at Sep 30, 2026. For fiscal 2025 it was $100.56M. The highest annual figure on record is $206.97M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.56M | – |
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $206.97M | – |
| FY2020 | Dec 31, 2020 | $0 | -100.0% |
| FY2019 | Dec 31, 2019 | $3.56M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $276.70M | +176.9% |
| Q2 FY2026 | Jun 30, 2026 | $176.29M | +77.6% |
| Q1 FY2026 | Mar 31, 2026 | $174.99M | +77.4% |
| Q4 FY2025 | Dec 31, 2025 | $100.56M | – |
| Q3 FY2025 | Sep 30, 2025 | $99.92M | – |
| Q2 FY2025 | Jun 30, 2025 | $99.28M | – |
| Q1 FY2025 | Mar 31, 2025 | $98.65M | -52.6% |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $208.21M | +5743.7% |
| Q4 FY2023 | Dec 31, 2023 | $206.97M | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $1.88M | – |
| Q4 FY2019 | Dec 31, 2019 | $3.56M | – |
See a number that looks wrong?